Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after...
Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention
About this item
Full title
Author / Creator
Publisher
Singapore: Springer Nature Singapore
Journal title
Language
English
Formats
Publication information
Publisher
Singapore: Springer Nature Singapore
Subjects
More information
Scope and Contents
Contents
Background
Treatment of recurrent malignant pleural mesothelioma (MPM) remains challenging. Our study examined the efficacy, tolerability, and safety of nivolumab with ipilimumab treatment for recurrent MPM after primary curative-intent surgery.
Methods
Treatment comprised 360 mg nivolumab every 3 weeks and 1 mg/kg of ipilimumab every 6 we...
Alternative Titles
Full title
Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2761985811
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2761985811
Other Identifiers
ISSN
1341-9625
E-ISSN
1437-7772
DOI
10.1007/s10147-023-02292-3
